Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human immune response to recombinant human proteins.

S Porter1

  • 1Cerus Corporation, 2411 Stanwell Drive, Concord, California 94520, USA. seth.porter@ceruscorp.com

Journal of Pharmaceutical Sciences
|November 7, 2000
PubMed
Summary

Recombinant protein therapies can trigger immune responses, potentially affecting drug efficacy and safety. However, antibody presence doesn't always mean treatment failure, and predicting clinical outcomes remains challenging.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oral health care pathways for patients with epidermolysis bullosa: A position statement from the European reference network for rare skin diseases.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same author

Plethora of drugs.

British dental journal·2022
Same author

Quantitative CT analysis using functional imaging is superior in describing disease progression in idiopathic pulmonary fibrosis compared to forced vital capacity.

Respiratory research·2018
Same author

Chikungunya fever: General and oral healthcare implications.

Oral diseases·2018
Same author

Establishing a clinical phenotype for cachexia in end stage kidney disease - study protocol.

BMC nephrology·2018
Same author

Changes in brain-behavior relationships following a 3-month pilot cognitive intervention program for adults with traumatic brain injury.

Heliyon·2017

Area of Science:

  • Immunology
  • Pharmacology
  • Biotechnology

Background:

  • Therapeutic proteins can elicit immune responses in patients.
  • These responses may alter drug exposure, efficacy, and safety profiles.
  • Concerns include anaphylaxis and autoimmunity.

Purpose of the Study:

  • To review literature on measuring and evaluating immune responses to recombinant human proteins in clinical trials.
  • To assess the impact of these immune responses on therapeutic outcomes.

Main Methods:

  • Literature review of clinical assessments of recombinant human protein therapies.
  • Analysis of reported immune responses and their clinical consequences.

Main Results:

  • Observed immune responses varied from none to antibody-mediated inactivation or accelerated clearance.

Related Experiment Videos

  • Antibody formation did not invariably compromise therapeutic viability.
  • Delivery frequency and route influenced responses, but predictive relationships were unclear.

    • Conclusions:

    • Immune responses to therapeutic proteins are a significant consideration.
    • While antibody presence doesn't always preclude successful treatment, predicting clinical impact is complex.
    • Further research is needed to establish clear predictive models for immune responses.